Results 41 to 50 of about 25,328 (173)

Durvalumab [PDF]

Reactions Weekly, 2020
  +6 more sources

A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

BMC Cancer, 2020
Background Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC).
Kyoichi Kaira, Atsuto Mouri, Shingo Kato, Kenichi Yoshimura, Hiroshi Kagamu, Kunihiko Kobayashi   +5 more
doaj   +1 more source

Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Radiation Oncology, 2023
Background The current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined with durvalumab consolidation therapy.
Mai Sakagami, Haruo Inokuchi, Nobutaka Mukumoto, Hiroshige Itoyama, Nobunari Hamaura, Mutsumi Yamagishi, Naoki Mukumoto, Shogo Matsuda, Daijiro Kabata, Keiko Shibuya   +9 more
doaj   +1 more source

Impact of Molecular Alterations on Survival in Biliary Tract Cancers: A Retrospective Belgian Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Biliary tract cancers (BTCs) are aggressive malignancies associated with a poor prognosis. Although molecular profiling is recommended to guide therapeutic decision‐making, real‐practice data on the prevalence and prognostic significance of genomic alterations in European BTC cohorts remain limited.
Jorine Arnouts, Léon C. van Kempen, Senada Koljenović, Helena Oliveres, Pieterjan Vanclooster, Hans Prenen, Caro De Weerdt, Siddharth Chhajlani, Geert Roeyen, Laure Sorber, Koen De Winne, Jonas Dahnoun, Greetje Vanhoutte, Timon Vandamme, Karen Zwaenepoel   +14 more
wiley   +1 more source

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events

Thoracic Cancer, 2020
Background Chemoradiotherapy followed by durvalumab is the standard treatment for the patients with local advanced non‐small cell lung cancer (NSCLC). There is a real‐world data about the management of adverse events, such as pneumonitis, according to ...
Yu Miura, Atsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, Ayako Shiono, Kosuke Hashimoto, Fuyumi Nishihara, Shun Shinomiya, Tomoe Akagami, Yoshitake Murayama, Takanori Abe, Shin‐ei Noda, Shingo Kato, Kunihiko Kobayashi, Hiroshi Kagamu   +14 more
doaj   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source

Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma

OncoImmunology, 2021
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials.
Rosalinda Arends, Xiang Guo, Paul G. Baverel, Ignacio González-García, James Xie, Nassim Morsli, Alejandro Yovine, Lorin K. Roskos   +7 more
doaj   +1 more source

Transoral Robotic Surgery in Head and Neck Oncology: A Scoping Review of Evidence, Technological Advancements, and Future Trajectories

Journal of Surgical Oncology, EarlyView.
ABSTRACT Robotic surgery has transformed head and neck cancer (HNC) treatment. This scoping review synthesizes evidence on transoral robotic surgery (TORS), focusing on applications, limitations, and future directions. Following PRISMA‐ScR guidelines, this review used the PCC framework (Population: HNC patients; Concept: technological advancements ...
Anna Luíza Damaceno Araújo, Karthik N. Rao, Juan P. Rodrigo, Vincent Vander Poorten, Orlando Guntinas‐Lichius, Alfio Ferlito, Luiz Paulo Kowalski   +6 more
wiley   +1 more source

When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature

Journal of Surgical Oncology, EarlyView.
ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu, Brian Longbottom, Hassan Aziz   +2 more
wiley   +1 more source

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis

Nature Communications
Although first-line immunotherapy plus chemotherapy has made substantial progress in extensive-stage small-cell lung cancer (ES-SCLC), the survival benefit remains limited.
Bo Zhang, Runbo Zhong, Chunlei Shi, Tianqing Chu, Wei Zhang, Huimin Wang, Xin Gan, Zhihong Zhang, Changbin Zhu, Xing Li, Wenzhong Su, Juan Li, Yanwei Zhang, Baohui Han, Hua Zhong   +14 more
doaj   +1 more source